Cytidine deaminase status as a marker of response to azacytidine treatment in MDS and AML patients
M Donnette, M Hamimed, J Ciccolini… - British Journal of …, 2023 - Wiley Online Library
Azacitidine (Aza) is a mainstay of treatment for patients with acute myeloid leukaemia (AML)
ineligible for induction chemotherapy and other high‐risk myelodysplastic syndromes …
ineligible for induction chemotherapy and other high‐risk myelodysplastic syndromes …
[HTML][HTML] Aberrant activation-induced cytidine deaminase gene expression links BCR/ABL1-negative classical myeloproliferative neoplasms
Conclusion: The results of our study suggest that although overexpression of AID does not
seem to support the JAK2 driver gene, it may contribute to the development of MPNs through …
seem to support the JAK2 driver gene, it may contribute to the development of MPNs through …
Activation-Induced Cytidine Deaminase Expression in Patients with Chronic Myeloid Leukemia
E Oguz, AD Aday, AS Yavuz - Experimed, 2022 - dergipark.org.tr
Objective: The findings on chronic myeloid leukemia (CML) patients suggest that clonal
tumoral cells tend to have additional mutations besides the formation of the BCR-ABL fusion …
tumoral cells tend to have additional mutations besides the formation of the BCR-ABL fusion …